Show simple item record

dc.contributor.authorHeaven, A
dc.contributor.authorBower, P
dc.contributor.authorDay, F
dc.contributor.authorFarrin, A
dc.contributor.authorFernadez, C
dc.contributor.authorFoster, M
dc.contributor.authorFoy, R
dc.contributor.authorHawkins, R
dc.contributor.authorHulme, C
dc.contributor.authorHumphrey, S
dc.contributor.authorLawton, R
dc.contributor.authorParker, C
dc.contributor.authorThompson, E
dc.contributor.authorWest, R
dc.contributor.authorClegg, A
dc.date.accessioned2024-01-29T13:19:28Z
dc.date.issued2024-01-02
dc.date.updated2024-01-29T10:48:59Z
dc.description.abstractBACKGROUND: Frailty is common in older age and is characterised by loss of biological reserves across multiple organ systems. These changes associated with frailty mean older people can be vulnerable to sudden, dramatic changes in health because of relatively small problems. Older people with frailty are at increased risk of adverse outcomes including disability, hospitalisation, and care home admission, with associated reduction in quality of life and increased NHS and social care costs. Personalised Care Planning offers an anticipatory, preventative approach to supporting older adults to live independently for longer, but it has not been robustly evaluated in a population of older adults with frailty. METHODS: Following an initial feasibility study, this multi-centre, individually randomised controlled trial aims to establish whether personalised care planning for older people improves health-related quality of life. It will recruit 1337 participants from general practices across Yorkshire and Humber and Mid-Mersey in the North of England. Eligible patients will be aged 65 and over with an electronic frailty index score of 0.21 or above, living in their own homes, without severe cognitive impairment and not in receipt of end-of-life care. Following confirmation of eligibility, informed consent and baseline data collection, participants will be individually randomised to the PeRsOnaliSed care Planning for oldER people with frailty (PROSPER) intervention or usual care in a 2.6:1 allocation ratio. Participants will not be blinded to allocation, but data collection and analysis will be blinded. The intervention will be delivered over 12 weeks by a Personal Independence Co-ordinator worker based within a voluntary sector organisation, Age UK. The primary outcomes are health-related quality of life, measured using both the physical and mental components of the Short-Form 12 Item Health Questionnaire at 12 months after randomisation. Secondary outcomes comprise activities of daily living, self-management capabilities and loneliness, admission to care homes, hospitalisations, and health and social care resource use at 12 months post randomisation. Parallel cost-effectiveness and process evaluations will be conducted alongside the trial. DISCUSSION: The PROSPER study will evaluate the effectiveness and cost-effectiveness of a personalised care planning approach for older people with frailty and inform the process of its implementation. TRIAL REGISTRATION: ISRCTN16123291 .  Registered on  28 August 2020.en_GB
dc.description.sponsorshipNational Institute for Health and Care Research (NIHR)en_GB
dc.format.extent8-
dc.format.mediumElectronic
dc.identifier.citationVol. 25, article 8en_GB
dc.identifier.doihttps://doi.org/10.1186/s13063-023-07857-1
dc.identifier.grantnumberRP-PG-0216-20010en_GB
dc.identifier.urihttp://hdl.handle.net/10871/135193
dc.identifierORCID: 0000-0003-2077-0419 (Hulme, Claire)
dc.language.isoenen_GB
dc.publisherBMCen_GB
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pubmed/38167481en_GB
dc.rights© The Author(s) 2023. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecom mons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.en_GB
dc.subjectFrailtyen_GB
dc.subjectOlder peopleen_GB
dc.subjectPersonalised-Care-Planningen_GB
dc.subjectQuality of lifeen_GB
dc.subjectRCTen_GB
dc.subjecteFIen_GB
dc.titlePeRsOnaliSed care Planning for oldER people with frailty (PROSPER): protocol for a randomised controlled trialen_GB
dc.typeArticleen_GB
dc.date.available2024-01-29T13:19:28Z
dc.identifier.issn1468-6708
exeter.article-number8
exeter.place-of-publicationEngland
dc.descriptionThis is the final version. Available on open access from BMC via the DOI in this recorden_GB
dc.descriptionAvailability of data and materials: Bradford Teaching Hospitals Foundation Trust (BTHFT) is the Data Controller. BTHFT will store non-trial data and the University of Leeds CTRU store trial data. Data will not be released prior to the end of the study, either for study publication or oral presentation purposes, without the permission of the TSC and subject to a data sharing agreement. During the archiving period, any requests for access to or copies of data will be considered by all collaborators in consultation. BTHFT will be the final arbiter of whether any disclosure/sharing should be agreed.en_GB
dc.identifier.eissn1745-6215
dc.identifier.journalTrialsen_GB
dc.relation.ispartofTrials, 25(1)
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_GB
dcterms.dateAccepted2023-12-06
dc.rights.licenseCC BY
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2024-01-02
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2024-01-29T13:17:50Z
refterms.versionFCDVoR
refterms.dateFOA2024-01-29T13:19:34Z
refterms.panelAen_GB
refterms.dateFirstOnline2024-01-02


Files in this item

This item appears in the following Collection(s)

Show simple item record

© The Author(s) 2023. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which 
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or 
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line 
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecom mons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Except where otherwise noted, this item's licence is described as © The Author(s) 2023. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecom mons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.